Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy has acquired the U.S. rights to a group of 13 branded dermatology products from Bristol-Myers Squibb, the Indian firm announced May 28. Bristol retains ex-U.S. rights to the products